- Sample ID
- Sample Name
- The MMAT patient who relapsed (first relapse after BCMA CAR-T therapy) after BCMA CAR-T cell therapy is from one of the 34 patients, who was enrolled in this clinical trial (ClinicalTrials.gov Identifier: NCT03661554)) on December 13, 2019, and a relapse was detected on October 27, 2021(namely as progression in this study).
- Subject type
Identification of potential resistance mechanisms and therapeutic targets for the relapse of BCMA CAR-T therapy in relapsed/refractory multiple myeloma through single-cell sequencing
- Homo sapiens
- Bone marrow CD45+ cells
- Fresh CD45+ cells enriched from two patients’ BM were resuspended in PBS with 0.04% bovine serum albumin to a final concentration of 700–1200 cells per μl. The Chromium Controller (10× Genomics) was used to generate single cell partitions and molecular barcoding. The Chromium Single Cell 3′ Reagent Kit v3.1 (10× Genomics) was used to generate single cell sequencing library. Eight thousand cells per sample were targeted in this study. All other steps were implemented according to the manufacturer’s protocols. Generated scRNA-seq libraries were run on the Illumina Novaseq (Zebrafish [Beijing] Technology Corporation, Beijing, China) for PE150 sequencing.
Project ID Project name Submitter Date OEP004164 Identification of potential resistance mechanisms and therapeutic targets for the relapse of BCMA CAR-T therapy in relapsed/refractory multiple myeloma through single-cell sequencing Shi, Jianxiang 2023-05-25
Experiment ID Experiment name Experiment type Experiment protocol Date OEX023766 OEX_Jianxiang_2305250914 Transcriptomic single cell Our group launched a single-arm, single-center clinical trial on BCMA CAR-T cells in the treatment of R/R-MM on April 11, 2018. The construction of anti-BCMA CAR, lentivirus production and production of CAR-T cells were described by our previous study . Thirty-four patients with R/R-MM were treated with BCMA CAR-T cell therapy and the preliminary results have been reported in the journal of leukemia (ClinicalTrials.gov Identifier: NCT03661554) . The ORR is 88.2% and the median progression-free survival time (PFS) is 12.1 months . To analyze the mechanism of relapse after BCMA CAR-T cell therapy, one patient at baseline (R/R-MM) and one patient at progression (first relapse after BCMA CAR-T therapy) were enrolled in the study. The patient relapse after BCMA CAR-T cell therapy is from one of the 34 patients, who was enrolled in this clinical trial on December 13, 2019, and a relapse was detected on October 27, 2021(namely as progression in this study). And the other patient is from the newly enrolled, who met the criteria for enrollment in the clinical trial on December 3, 2021, after screening (namely as baseline in this study). The detailed characteristics of these two patients including clinicopathological features, bone marrow plasma cell ratio, staging and so on were comparable and similar (Additional file 1: Table S1). Five milliliters (mL) of bone marrow were then extracted from the two patients, and the CD45+ cells were enriched with human CD45 microbeads, according to the manufacturer’s instructions (Miltenyi Biotec, Cat#:130-045-801). The CD45+ cells were subsequently sent for 10 × genomics ScRNA-seq. 2023-05-25
Run ID Run Name Project Experiment Sample Data Date OER396124 OER_Jianxiang_2305252246 OEP004164 OEX023766 OES308608 2 2023-05-25
- Create Date
- Last Modified
- Jianxiang Shi,Zhengzhou University